Past Clinical Trials


 Wet Age-Related Macular Degeneration


A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration


A Phase III study randomized, parallel-group, multicenter, double-masked study of the safety and efficacy of Anecortave Acetate for Depot Suspension (15mg and 30 mg) versus sham administration in arresting the progression of non-exudative (dry) AMD in patients who are at risk for progressing to exudative (wet) AMD. 


A Phase I Single Ascending Dose Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Intravitreous Injections Of E10030 (Anti-Pdgf Pegylated Aptamer) Monotherapy And Of E10030 Given In Combination With Lucentis 0.5mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration


A Phase II Multicenter, Randomized, Double-Masked, Placebo Controlled, Dose- Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Genentech & Novartis   SAILOR

A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)


A Phase II/III Multi-Center, Randomized, Clinical Trial to evaluate the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with neovascular Age-Related Macular Degeneration (AMD)

Genentech  ANCHOR

 A Phase III  study which compares efficacy of subjects who have Lucentis®, injected into the eye once a month for two years, to PDT (Visudyne®), administered to the eye every three months for two years. in patients with wet  Age-related Macular Degeneration (AMD)


Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion

Diabetic Macular Edema

Alimera (FAME) 

A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema


A Phase II study for evaluation of Anti-VEGF therapy, Bevacizumab (Avastin)   Intravitreal injections in Subjects with Diabetic Macular Edema



Back to Research